Dear Valued Partners and Healthcare Providers,

For more than five years, Agios has been committed to educating on the importance of diagnosis and breaking down barriers in genetic testing for patients with hemolytic anemias. Our collaboration with Revvity Omics resulted in the creation of the Anemia ID program, which offers free testing for patients with suspected hereditary anemias. This initiative aimed to provide crucial information that could guide informed decisions, improve quality of life, and identify new treatment options. Agios took a bold step by creating this sponsored testing program, which was unprecedented in this field.

As we continue to evolve, Agios is expanding our organizational scope to support a growing group of patients and providers across PK deficiency, thalassemia, sickle cell disease, and more. We must carefully prioritize our efforts to support this broader mission and have a positive impact across all of these communities. Therefore, we have made the difficult decision to discontinue the Anemia ID program.

Going forward, we will continue to educate on the importance of diagnosing patients with hemolytic anemias leveraging the tools available and will continue to provide robust financial and other support for pyruvate kinase deficiency patients through our myAgios patient support program.

Anemia ID test kits will be available for order at no cost on the Anemia ID website (www.anemiaid.com) through December 15, 2024. All specimens received prior to December 31, 2024 will be tested at no cost under the Anemia ID program.

After that date, the existing Anemia ID next-generation sequencing (NGS) panel, which examines 50+ genes and 30+ disorders, will be commercially available independently through Revvity Omics. Additionally, there are other commercial and academic labs offering NGS panel tests for hereditary anemias (www.anemiaid.com/testing-resources.pdf).

We take pride in the groundbreaking work accomplished during the past half-decade. Our partners have meticulously analyzed thousands of samples, leading to hundreds of confirmed diagnoses that have positively impacted countless lives, and many have also received genetic counseling through InformedDNA. This achievement reflects our dedication to advancing patient care.

Anemia ID was intended to serve the broader hemolytic anemia community, including pyruvate kinase (PK) deficiency, a disease that was previously not well known or understood. We believe that Anemia ID has indeed helped to make meaningful progress for this community by improving awareness and diagnosis of these conditions.

We are immensely proud of the positive impact Anemia ID has had for patients. Our commitment to innovation and improving healthcare remains unwavering. We appreciate your ongoing support and look forward to continuing our journey together.

Sincerely,

Tsveta Milanova
Chief Commercial Officer
Agios Pharmaceuticals

PKD-US-1275